Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- pelvic mass
- ascites
- pleural effusion
Outros fatores diagnósticos
- gastrointestinal symptoms
- urinary urgency or frequency
- symptom duration >3 months
- abdominal distention
- pelvic/abdominal pain or pressure
Fatores de risco
- genetic mutations associated with hereditary ovarian cancer
- increasing age
- family history of ovarian cancer, breast cancer, colorectal cancer, and/or endometrial cancer
- never used combined oral contraceptives
- nulliparity
- obesity
- hormone therapy
- endometriosis
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- pelvic ultrasound
- CA-125
- histopathology
Investigações a serem consideradas
- genetic testing
- PET, PET-CT, or PET/MRI
- MRI
- CT scan
- biomarker tests
Algoritmo de tratamento
surgical candidate, intraoperative histology confirmed disease
poor surgical candidate, biopsy confirmed disease
platinum-sensitive recurrent disease
platinum-resistant recurrent or refractory disease
Colaboradores
Autores
Sareena Singh, MD
Gynecologic Oncologist
Aultman Medical Group
Northeast Ohio Medical University
Canton
OH
Declarações
SS declares that she has no competing interests.
Agradecimentos
Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.
Declarações
JCC and AEA declare that they have no competing interests.
Revisores
Michael P. Hopkins, MD, MEd
Chairman
Obstetrics and Gynecology
Northeast Ohio Universities of Medicine (NEOMED)
Rootstown
OH
Declarações
MPH declares that he has no competing interests.
Ritu Salani, MD
Gynecologic Oncology Fellow
Johns Hopkins Medical Institutions
Baltimore
MD
Declarações
RS declares that she has no competing interests.
Susan A. Davidson, MD
Associate Professor
Chief, Gynecologic Oncology
Department of Obstetrics & Gynecology (UCD)
University of Colorado Cancer Center
Aurora
CO
Declarações
SAD declares that she has no competing interests.
Khadra Galaal, MBChB, MPH, MRCOG
Consultant Gynaecological Oncologist
Northern Gynaecological Oncology Centre
Queen Elizabeth Hospital
Gateshead
UK
Declarações
KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.
Jill Tseng, MD
Assistant Clinical Professor of Gynecologic Oncology
University of California, Irvine
Orange
CA
Declarações
JT declares that she has no competing interests.
Diagnósticos diferenciais
- Irritable bowel syndrome (IBS)
- Metastases to the ovary
- Endometriosis
Mais Diagnósticos diferenciaisDiretrizes
- Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
- Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment
Mais DiretrizesFolhetos informativos para os pacientes
Ovarian cancer: what is it?
Ovarian cancer: what treatments work?
Mais Folhetos informativos para os pacientesConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal